

Result update

SPIMACO

Sector : Healthcare

HOLD

9 August 2026

- **Recovery remains intact despite the macro slowdown.** Revenue reached SAR 493mn in 2Q26, up 23.0% YoY and 19.2% above our estimate, supported by strong growth across core pharma (+25.3% YoY), distribution services (+9.6% YoY), and healthcare (+11.8% YoY).
- **Margins remained resilient, supported by a higher contribution from value-added brands and improved procurement costs.** Gross profit increased broadly in line with revenue, while operating profit rose 44.4% YoY, although the operating margin was slightly below our expectations. Net profit stood at SAR 70mn, up 93.8% YoY but 3.7% below our estimate.
- **We broadly maintain our 2026e estimates following the 2Q26 results. We raise our target price slightly to SAR 32.64 per share. As there is limited upside from current levels, we maintain our Hold rating.**


SPIMACO reported consolidated revenue of SAR 493mn in 2Q26, its highest quarterly revenue in the past 12 quarters and representing a 23.0% YoY increase. We had moderated our topline expectations given the broader slowdown in the Saudi pharmaceutical market and trends observed across peers. However, SPIMACO significantly outperformed our forecast, with revenue exceeding our estimate by 19.2%, driven by a favorable product mix, greater focus on higher-value brands, and robust tender activity. As one of the largest pharmaceutical manufacturers in the region, SPIMACO is well positioned to benefit from the continued development of the domestic pharmaceutical industry, although the current market slowdown could moderate growth in the coming quarters. The company has also entered into multiple strategic partnerships with global pharmaceutical players, including Boston Scientific, AstraZeneca, and CanSinoBIO, which we expect to support volume growth and broaden its product portfolio over time. The core pharmaceutical manufacturing segment delivered strong growth of 25.3% YoY during the quarter. Distribution services, which contributed approximately 4.7% of consolidated revenue, increased 9.6% YoY, while the healthcare segment grew 11.8% YoY. The contribution of the Saudi market declined marginally to 87.7%, reflecting increasing contributions from international markets.

Gross margin expanded modestly by 30bps YoY, supported by a higher contribution from value-added products and improved raw material procurement costs. Management also continued to exercise cost discipline, including lower R&D expenditure, which supported profitability at the operating level. Operating margin expanded by 268bps YoY, although it remained below our expectation of a further improvement from the previous quarter's high of 20.7%. Operating profit increased 44.4% YoY, but was 4.6% below our forecast. Despite the significant topline outperformance, net profit was slightly below our expectations, reaching SAR 70mn, up 93.8% YoY. For the 1H26 the company reported a net profit of SAR 138.3mn (+24.4% YoY).

Target price (SAR) 32.64

Current price (SAR) 31.44

Return 3.80%



Exchange Saudi Arabia
Index weight (%) 0.2%

(mn)	SAR	USD
Market Cap	3,773	1,019
Enterprise value	4,913	1,327

Major shareholders

ARAB CO DRUG IND & M	10.5%
Vanguard Group Inc/T	2.1%
Blackrock Inc	1.0%
Others	86.4%

Valuation Summary (TTM)

PER TTM (x)	12.1
P/Book (x)	1.8
EV/EBITDA (x)	10.8
Dividend Yield (%)	0.0
Free Float (%)	86%
Shares O/S (mn)	120
YTD Return (%)	21%
Beta	1.1

Key ratios	2023	2024	2025
EPS (SAR)	-0.08	0.27	1.64
BVPS (SAR)	13.90	12.76	14.68
DPS (SAR)	0.00	0.00	0.00
Payout ratio (%)	0%	0%	0%

Price performance (%)	1M	3M	12M
SPIMACO	4%	6%	21%
Tadawul All Share Index	0%	-2%	-1%

52 week	High	Low	CTL*
Price (SAR)	33.12	24.96	26.0

* CTL is % change in CMP to 52wk low



Valuation: SPIMACO has made significant progress in its recovery, with topline growth remaining sustainable over recent quarters. Management's efforts to improve profitability by phasing out legacy loss-making and low-margin products are increasingly evident in the company's margin profile. The continued focus on higher-value brands, cost optimization, and strategic partnerships should provide further support to earnings over the medium term. However, approximately 90% of revenue continues to be generated from the Saudi market, leaving the company exposed to the ongoing moderation in domestic pharmaceutical demand. We therefore expect near-term growth to remain relatively constrained. At the same time, increasing exposure to international markets, including Iraq, Syria, and selected African markets, provides an opportunity to diversify the revenue base and support longer-term growth. We also view the company's efforts to broaden its product portfolio through partnerships with leading global pharmaceutical players positively. These arrangements should improve product depth and potentially accelerate volume growth as new products and partnerships mature. Following the 2Q26 results, we broadly maintain our 2026e revenue and earnings estimates, and marginally raise our target price to SAR 32.64 per share. At current levels, we believe the stock is fairly valued, with the share price largely reflecting both the near-term domestic market slowdown and the company's longer-term recovery potential. Accordingly, we maintain our Hold rating on SPIMACO.



Income Statement (In SAR mn)	2023	2024	2025	2026e	2027e	2028e	2029e	2030e
Revenue	1,653	1,682	1,707	1,783	1,943	2,119	2,221	2,328
Direct Costs	-945	-845	-874	-878	-962	-1,049	-1,099	-1,152
Gross profit	708	837	833	905	981	1,070	1,121	1,176
Selling and marketing expenses	-349	-333	-289	-269	-291	-318	-333	-349
General and administrative expenses	-255	-271	-235	-232	-272	-297	-300	-314
Research and development expenses	-41	-76	-60	-46	-58	-64	-67	-70
Other expenses	27	-19	18	-19	-19	-21	-22	-23
Operating Profit	89	137	266	340	340	371	400	419
EBITDA	115	211	364	416	436	471	503	526
Finance cost	-70	-88	-98	-79	-75	-63	-57	-51
Other income (Net)	17	23	38	32	30	30	30	30
Profit before Zakat (PBT)	36	72	206	294	295	338	373	398
Zakat and income tax	-45	-40	-9	-31	-30	-34	-37	-40
Net Profit/ loss bf disc operations	-9	32	197	263	266	304	336	358
Loss from discounted operations	-	-	-	-	-	-	-	-
Net Profit	-9	32	197	263	266	304	336	358

Balance Sheet (in SAR mn)	2023	2024	2025	2026e	2027e	2028e	2029e	2030e
Property, plant and equipment	1,272	1,574	1,544	1,522	1,496	1,475	1,454	1,434
Assets under construction	583	172	234	273	320	376	437	503
Intangible assets	17	102	104	93	112	129	145	160
Right of use assets	32	26	7	11	15	18	21	24
Other non current assets	86	89	104	108	85	85	85	85
Non-current assets	2,049	1,963	1,992	2,007	2,028	2,083	2,142	2,207
Inventories	589	646	611	527	577	629	660	691
Trade and other receivables	924	1,175	1,176	1,337	1,457	1,377	1,443	1,513
Time deposits	116	155	180	151	151	151	151	151
Cash and cash equivalents	160	122	204	306	311	286	321	368
Other current assets	164	243	179	143	155	170	178	186
Current assets	1,975	2,356	2,376	2,495	2,652	2,614	2,753	2,910
ASSETS	4,024	4,319	4,367	4,502	4,680	4,696	4,895	5,117
Share capital	1,200	1,200	1,200	1,200	1,200	1,200	1,200	1,200
Reserves	319	317	337	-23	-23	-23	-23	-23
Retained earnings	-4	-120	79	703	969	1,193	1,438	1,696
Equity before NCI	1,507	1,378	1,597	1,860	2,126	2,350	2,595	2,852
Non-controlling interest	161	153	166	184	210	232	257	282
EQUITY	1,668	1,531	1,762	2,044	2,336	2,583	2,851	3,134
Loans and borrowings	575	462	462	486	386	286	286	286
Lease liability	11	8	5	1	1	1	1	1
Employees' end of service benefits	283	222	187	155	181	198	200	209
Deferred income	38	40	40	39	39	39	39	39
Contract liabilities	44	45	52	55	55	55	55	55
Non-current liabilities	951	778	746	735	662	578	580	590
Loans and borrowings	525	1,039	965	960	860	760	660	560
Trade payable and other liabilities	507	568	496	351	385	315	330	346
Contract liabilities	125	170	176	219	240	262	275	288
Other current liabilities	242	234	223	192	197	199	199	199
Current liabilities	1,405	2,010	1,860	1,723	1,682	1,536	1,463	1,393
LIABILITIES	2,356	2,788	2,606	2,458	2,344	2,114	2,044	1,983
EQUITY AND LIABILITIES	4,024	4,319	4,368	4,502	4,680	4,696	4,895	5,117

Cash Flow (In SAR mn)	2023	2024	2025	2026e	2027e	2028e	2029e	2030e
Cash from operations	48	-331	273	165	213	348	350	371
Investing cash flow	-172	-93	-85	-143	-155	-170	-178	-186
Financing cash flow	-32	381	-105	78	-52	-203	-137	-137
Change in cash	-175	-38	82	101	5	-25	35	47
Beginning cash	336	160	123	204	306	311	286	321
Ending cash	160	123	204	306	311	286	321	368



Ratio Analysis	2023	2024	2025	2026e	2027e	2028e	2029e	2030e
Per Share								
EPS (SAR)	-0.1	0.3	1.6	2.2	2.2	2.5	2.8	3.0
BVPS (SAR)	13.9	12.8	14.7	17.0	19.5	21.5	23.8	26.1
DPS (SAR)	-	-	-	-	0.7	0.8	0.8	0.9
FCF per share (SAR)	-1.0	-3.5	1.6	0.2	0.5	1.5	1.4	1.5
Valuation								
Market Cap (SAR mn)	4,536	3,834	3,127	3,773	3,773	3,773	3,773	3,773
EV (SAR mn)	5,495	5,224	4,356	4,913	4,714	4,538	4,401	4,252
EBITDA	115	211	364	416	436	471	503	526
P/E (x)	-499.8	120.4	15.9	14.4	14.2	12.4	11.2	10.5
EV/EBITDA (x)	47.9	24.8	12.0	11.8	10.8	9.6	8.8	8.1
Price/Book (x)	2.7	2.5	1.8	1.8	1.6	1.5	1.3	1.2
Dividend Yield (%)	0.0%	0.0%	0.0%	0.0%	2.1%	2.4%	2.7%	2.9%
Price to sales (x)	2.7	2.3	1.8	2.1	1.9	1.8	1.7	1.6
EV to sales (x)	3.3	3.1	2.6	2.8	2.4	2.1	2.0	1.8
Liquidity								
Cash Ratio (x)	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.3
Current Ratio (x)	1.4	1.2	1.3	1.4	1.6	1.7	1.9	2.1
Quick Ratio (x)	1.0	0.9	0.9	1.1	1.2	1.3	1.4	1.6
Returns Ratio								
ROA (%)	-0.2%	0.7%	4.5%	5.8%	5.7%	6.5%	6.9%	7.0%
ROE (%)	-0.5%	2.1%	11.2%	12.9%	11.4%	11.8%	11.8%	11.4%
ROCE (%)	-0.3%	1.4%	7.8%	9.5%	8.9%	9.6%	9.8%	9.6%
Cash Cycle								
Inventory turnover (x)	1.6	1.3	1.4	1.7	1.7	1.7	1.7	1.7
Accounts Payable turnover (x)	1.9	1.5	1.8	2.5	2.5	3.3	3.3	3.3
Receivables turnover (x)	1.5	1.2	1.3	1.2	1.2	1.4	1.4	1.4
Inventory days	228	279	255	219	219	219	219	219
Payable Days	196	245	207	146	146	110	110	110
Receivables days	240	308	290	303	303	266	266	266
Cash Cycle	272	341	338	376	376	376	376	376
Profitability Ratio								
Net Margins (%)	-0.5%	1.9%	11.5%	14.7%	13.7%	14.4%	15.1%	15.4%
EBITDA Margins (%)	6.9%	12.5%	21.3%	23.3%	22.5%	22.2%	22.6%	22.6%
PBT Margins (%)	2.2%	4.3%	12.0%	16.5%	15.2%	16.0%	16.8%	17.1%
EBIT Margins (%)	5.4%	8.2%	15.6%	19.1%	17.5%	17.5%	18.0%	18.0%
Effective Tax Rate (%)	-125.1%	55.8%	4.3%	10.6%	10.0%	10.0%	10.0%	10.0%
Leverage								
Total Debt (SAR mn)	1,119	1,513	1,433	1,446	1,252	1,051	949	848
Net Debt (SAR mn)	959	1,390	1,229	1,140	942	765	628	479
Debt/Total Assets (x)	0.3	0.4	0.3	0.3	0.3	0.2	0.2	0.2
Debt/Equity (x)	0.7	1.0	0.8	0.7	0.5	0.4	0.3	0.3
Net Debt/Equity (x)	0.6	0.9	0.7	0.6	0.4	0.3	0.2	0.2


Key contacts

Research Team

Joice Mathew	Manna Thomas ACCA	Contact Address
Sr. Manager - Research	Research Associate	P. O Box: 2566; P C 112
E-Mail: joice@usoman.com	Email: manna.t@usoman.com	Sultanate of Oman
Tel: +968 2476 3311	Tel: +968 2476 3347	Tel: +968 2476 3300

Rating Criteria and Definitions

Rating



Rating Definitions

Strong Buy	This recommendation is used for stocks whose current market price offers a deep discount to our 12-Month target price and has an upside potential in excess of 20%
Buy	This recommendation is used for stocks whose current market price offers a discount to our 12-Month target price and has an upside potential between 10% to 20%
Hold	This recommendation is used for stocks whose current market price offers a discount to our 12-Month target price and has an upside potential between 0% to 10%
Neutral	This recommendation is used for stocks whose current market price offers a premium to our 12-Month target price and has a downside side potential between 0% to -10%
Sell	This recommendation is used for stocks whose current market price offers a premium to our 12-Month target price and has a downside side potential between -10% to -20%
Strong Sell	This recommendation is used for stocks whose current market price offers a premium to our 12-Month target price and has a downside side potential in excess of 20%
Not rated	This recommendation used for stocks which does not form part of Coverage Universe

Disclaimer

This document is not for public distribution and has been furnished to you solely for your information and must not be reproduced or redistributed to any other person. Persons into whose possession this document may come are required to observe these restrictions. Opinion expressed is our current opinion as of the date appearing on this material only. We do not undertake to advise you as to any change of our views expressed in this document. While we endeavor to update on a reasonable basis the information discussed in this material, United Securities, its subsidiaries and associated companies, their directors and employees are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that prevent us from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. The information in this document has been printed on the basis of publicly available information, internal data and other reliable sources believed to be true and are for general guidance only. While every effort is made to ensure the accuracy and completeness of information contained, the company takes no guarantee and assumes no liability for any errors or omissions of the information. No one can use the information as the basis for any claim, demand or cause of action.

Recipients of this material should rely on their own investigations and take their own professional advice. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult their own advisors to determine the merits and risks of such an investment. Price and value of the investments referred to in this material may go up or down. Past performance is not a guide for future performance. United Securities LLC, and affiliates, including the analyst who has issued this report, may, on the date of this report, and from time to time, have long or short positions in, and buy or sell the securities of the companies mentioned herein or engage in any other transaction involving such securities and earn brokerage or compensation or act as advisor or have other potential conflict of interest with respect to company/ies mentioned herein or inconsistent with any recommendation and related information and opinions. United Securities LLC and affiliates may seek to provide or have engaged in providing corporate finance, investment banking or other advisory services in a merger or specific transaction to the companies referred to in this report, as on the date of this report or in the past.